Actively Recruiting
A 24-week rPMS Study in Real-world Setting for Enerzair
Led by Novartis Pharmaceuticals · Updated on 2026-04-02
600
Participants Needed
20
Research Sites
252 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This surveillance was designed as a prospective, open-label, multicenter, single-arm, non-interventional, observational study to evaluate the safety and effectiveness of Enerzair inhalation capsule for up to 24 weeks under routine clinical practice.
CONDITIONS
Official Title
A 24-week rPMS Study in Real-world Setting for Enerzair
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adults 18 years of age or older with a physician's diagnosis of asthma
- Currently prescribed Enerzair inhalation capsule (150/50/80 or 150/50/160 mcg) via Breezhaler according to approved label
- Willing to participate and provide signed consent after clear explanation of study objectives and nature
You will not qualify if you...
- Hypersensitivity to Enerzair or any of its ingredients
- Hereditary lactose intolerance conditions such as galactose intolerance, Lapp lactose deficiency, or glucose-galactose malabsorption
- Experiencing acute asthma symptoms needing a short-acting bronchodilator
- Currently participating in other interventional clinical trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 20 locations
1
Novartis Investigative Site
Daegu, Dalseo gu, South Korea, 42602
Actively Recruiting
2
Novartis Investigative Site
Wŏnju, Gangwon-do, South Korea, 26426
Actively Recruiting
3
Novartis Investigative Site
Bucheon-si, Gyeonggi-do, South Korea, 14584
Completed
4
Novartis Investigative Site
Bundang Gu, Gyeonggi-do, South Korea, 13620
Actively Recruiting
5
Novartis Investigative Site
Goyang-si, Gyeonggi-do, South Korea, 10475
Completed
6
Novartis Investigative Site
Jeonju, Jeollabuk-do, South Korea, 561 712
Actively Recruiting
7
Novartis Investigative Site
Suncheon, Jeollanam-do, South Korea, 540-719
Completed
8
Novartis Investigative Site
Cheongju-si, North Chungcheong, South Korea, 28644
Active, Not Recruiting
9
Novartis Investigative Site
Seoul, Seoul, South Korea, 06351
Actively Recruiting
10
Novartis Investigative Site
Busan, South Korea, 49201
Actively Recruiting
11
Novartis Investigative Site
Daegu, South Korea, 705703
Actively Recruiting
12
Novartis Investigative Site
Gwangju, South Korea, 501171
Actively Recruiting
13
Novartis Investigative Site
Gyeonggi-do, South Korea, 14353
Active, Not Recruiting
14
Novartis Investigative Site
Gyeongsangnam Do, South Korea, 630-522
Actively Recruiting
15
Novartis Investigative Site
Seoul, South Korea, 03722
Actively Recruiting
16
Novartis Investigative Site
Seoul, South Korea, 03722
Active, Not Recruiting
17
Novartis Investigative Site
Seoul, South Korea, 04763
Actively Recruiting
18
Novartis Investigative Site
Seoul, South Korea, 05505
Actively Recruiting
19
Novartis Investigative Site
Seoul, South Korea, 06273
Actively Recruiting
20
Novartis Investigative Site
Seoul, South Korea, 2447
Actively Recruiting
Research Team
N
Novartis Pharmaceuticals
CONTACT
N
Novartis Pharmaceuticals
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here